The Spot Sign for predicting and treating ICH growth study (STOP-IT) is a phase II study that seeks to determine whether patients who suffer an intracranial hemorrhage (ICH) and show contrast extravasation on CT angiography (CTA) can benefit from a coagulation factor treatment with recombinant Factor Vila (rFVIIa). In an unselected population of patients with ICH preliminary data showed that contrast extravasation during CTA (spot sign) predicts hematoma expansion and poorer neurological outcome. Patients with signs of ongoing ICH expansion may be more likely to benefit from rFVIIa treatment. In the STOP-IT study adult patients who present within 6 hours of an acute ICH will receive a head CT and CTA. Patients who show the spot sign, which is contrast extravasation into the hematoma seen on CTA will be randomized to receive 80ug/kg fFVIIa or placebo. We plan to contribute 30 patients in San Diego to a total of 364 patients study-wide over 5 years. The study will show if the spot sign can be identified reliably, if the spot sign correlates with outcome and if patients with a positive spot the spot sign benefit from treatment with rFVIIa. The primary outcome is measured as the percent of patients in each treatment group with hematoma that growth from baseline to the 24 hours CT scan.. This trial fits well with the other projects proposed by UCSD SPOTRIAS since there is no overlap with other trials, and the stroke team (see Core C) will be called in for intracerebral hemorrhages due to Code Stroke activation prior to a CT head scan.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS044148-07
Application #
7871309
Study Section
Special Emphasis Panel (ZNS1)
Project Start
Project End
Budget Start
2009-05-01
Budget End
2010-04-30
Support Year
7
Fiscal Year
2009
Total Cost
$62,098
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Chen, P M; Nguyen, D T; Ho, J P et al. (2018) Factors Influencing Acute Stroke Thrombolytic Treatments in Hispanics In the San Diego Region. Austin J Cerebrovasc Dis Stroke 5:
Lyden, Patrick; Hemmen, Thomas; Grotta, James et al. (2016) Results of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2). Stroke 47:2888-2895
Guluma, Kama Z; Liebeskind, David S; Raman, Rema et al. (2015) Feasibility and Safety of Using External Counterpulsation to Augment Cerebral Blood Flow in Acute Ischemic Stroke-The Counterpulsation to Upgrade Forward Flow in Stroke (CUFFS) Trial. J Stroke Cerebrovasc Dis 24:2596-604
Neil, William P; Raman, Rema; Hemmen, Thomas M et al. (2015) Association of Hispanic ethnicity with acute ischemic stroke care processes and outcomes. Ethn Dis 25:19-23
Schlick, Konrad H; Hemmen, Thomas M; Lyden, Patrick D (2015) Seizures and Meperidine: Overstated and Underutilized. Ther Hypothermia Temp Manag 5:223-7
Spokoyny, Ilana; Raman, Rema; Ernstrom, Karin et al. (2015) Defining mild stroke: outcomes analysis of treated and untreated mild stroke patients. J Stroke Cerebrovasc Dis 24:1276-81
Spokoyny, Ilana; Raman, Rema; Ernstrom, Karin et al. (2015) Accuracy of First Recorded ""Last Known Normal"" Times of Stroke Code Patients. J Stroke Cerebrovasc Dis 24:2467-73
Coffman, Clarity R; Raman, Rema; Ernstrom, Karin et al. (2015) The ""DeyeCOM Sign"": Predictive Value in Acute Stroke Code Evaluations. J Stroke Cerebrovasc Dis 24:1299-304
Lyden, Patrick D; Hemmen, Thomas M; Grotta, James et al. (2014) Endovascular therapeutic hypothermia for acute ischemic stroke: ICTuS 2/3 protocol. Int J Stroke 9:117-25
Spokoyny, Ilana; Raman, Rema; Ernstrom, Karin et al. (2014) Imaging negative stroke: diagnoses and outcomes in intravenous tissue plasminogen activator-treated patients. J Stroke Cerebrovasc Dis 23:1046-50

Showing the most recent 10 out of 53 publications